¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ : 2021-06-04

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
(¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ : 2021-06-04
±³À°ÀÏÀÚ : 2021-06-04
±³À°Àå¼Ò : ¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ µ¿½Ã °³ÃÖ (*¿ÀÇÁ¶óÀÎ: ÀÎÅÍÄÁƼ³ÙÅ» ¼­¿ï ÄÚ¿¢½º B1 ºñ¹Ùü·ë)  
±³À°ÁÖÁ¦ : (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ      
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ  
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520  
À̸ÞÀÏ : retina@retina.or.kr      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 5Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 5 ½Ã°£ 48ºÐ  
¼¼ºÎ¼ö°­·á : 50,000¿ø      
ºñ°í       
       
±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 06¿ù 04ÀÏ  13:05~13:25 Where steroids fit for DME in the Anti-VEGF era?  »ç°ø¹Î(¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  13:25~13:40 Non-infectious uveitis¿¡¼­ ¿ÀÀúµ¦½º¢ç¿Í È޹̶ó¢çÀÇ Ä¡·áÀû À§Ä¡¿Í ½ÇÁ¦ ÀÓ»ó Àû¿ë  ¿ì¼¼ÁØ(¼­¿ïÀÇ´ë) 
Åä·Ð 06¿ù 04ÀÏ  13:40~13:50 Discussion  »ç°ø¹Î¿ì¼¼ÁØ(¿µ³²ÀÇ´ë¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  13:50~14:00 Heterogeneity of Inherited Cone Dysfunction Disorders with Normal Fundus appearance  ÁÖ±¤½Ä(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:00~14:10 Retinitis Pigmentosa Sine Pigmento: Clinical Spectrum and Pigment Development  ÀÌÀº°æ(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:10~14:20 Myopic Disc Deformation as a Prognostic Factor of Myopic Choroidal Neovascularization: A 6-year Follow-up Study  ±èÀ±Àü(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:20~14:30 Clinical features of wide macular posterior staphyloma: Primary versus Compound staphyloma  ¹Ú¿îö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:30~14:40 Therapeutic Efficacy of Autologous Platelet Concentrate on Macular hole with High myopia, Large Macular Hole or Recurrent Macular Hole: A Multicenter Randomized Clinical Trial  ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:40~14:50 È²¹Ý¿ø°ø ¼ö¼ú ÈÄ È²¹ÝÀÇ º¯Çü°ú º¯Çü½Ã  ÀÌÁöÀº(À̾ȰúÀÇ¿ø) 
±³À°½Ã°£ 06¿ù 04ÀÏ  14:50~15:00 ¼Ò¾Æ ¸Á¸· ȯÀÚÀÇ Àü½Å¸¶ÃëÇÏ °Ë»ç (Exam under anesthesia; EUA)  ±è»óÁø(¼º±Õ°üÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:05~15:15 ÀÎü À¯·¡ ¸Á¸· ¿À°¡³ëÀÌµå ³» ¸Á¸· ½Å°æÀý ¼¼Æ÷ÃþÀÇ Çü¼º ¹× lamination¿¡¼­ mTORC1 °æ·ÎÀÇ ¿ªÇÒ ±Ô¸í  ÇÑÁ¤¿ì(¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:15~15:25 Relationship between retinal capillary vessel density of OCT angiography and intraocular pressure in pig  ÃÖ¹ÌÇö(°í·ÁÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:25~15:35 Impact of Kidney Transplantation on the Risk of Retinal Vein Occlusion in End-stage Renal Disease  ¿À¹é·Ï(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:35~15:45 Retinal Vascular Occlusion in Moyamoya Disease: Case series and Literature Review  À̽±Ô(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:45~15:55 Deep learning-based cardiovascular risk stratification using coronary artery calcium scores predicted from retinal photographs  ÀÓÇüÅÃ(SERI) 
±³À°½Ã°£ 06¿ù 04ÀÏ  15:55~16:05 Customized Color Settings of Digitally Assisted Vitreoretinal Surgery Enable a Decrease in the Dye Concentration during Macular Surgery  ¹Úµ¿È£(°æºÏÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:10~16:16 ¿À¿° Á¡Åº¹°Áú¿¡ ÀÇÇØ Áý´Ü¹ß»ýÇÑ ¼ú ÈÄ Çª»ç¸®¿ò Áø±Õ ¾È³»¿° ȯÀÚ¿¡¼­ ÀÌÂ÷ Àΰø¼öÁ¤Ã¼ »ðÀÔ¼ú  ±èÁß°ï(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:16~16:22 Successful PVD induction; The outcome of vitreous surgery depends a lot on the accomplishment of this procedure  À̺´·Î(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:22~16:28 New Method of Macular hole surgery by drawing macula  ¿ÀÇö¼·(´©³×¾È°ú) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:28~16:34 Retinal toxicity due to long-standing migratory perfluorocarbon  ½Å¿ë¿î(ÇѾçÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:34~16:40 Å« ¸Æ¶ô¸· Èæ»öÁ¾ÀÇ ¼ö¼úÀû Ä¡·á  ±è¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:40~16:46 È²¹ÝÇÏ Á¶Á÷ Çö󽺹̳ë°Õ È°¼ºÀÎÀÚ¿Í °ø±â ÁÖÀÔ¼úÀ» ÅëÇÑ ¸Á¸·ÇÏ ÃâÇ÷ÀÇ È£Àü »ç·Ê  ÀÌÇü¿ì(°Ç±¹ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:46~16:52 4±ºµ¥ Á¢ÇպΠ·»Áî °ø¸·°íÁ¤¼úÀ» ½±°Ô ¼öÇàÇÏ´Â ¹æ¹ý  ¹Ú¹Î¼±(ÇѸ²ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:52~16:58 Acute intraoperative hypotony: Cause, Management and Prevention  Àå¿ìÇõ(Àå¿ìÇõ¾È°ú) 
±³À°½Ã°£ 06¿ù 04ÀÏ  16:58~17:04 ¹Ì¼÷¾Æ¸Á¸·º´Áõ¿¡¼­ÀÇ Ç×Ç÷°ü³»ÇǼºÀåÀÎÀÚ ÁÖ»çÄ¡·á½Ã À¯ÀÇÇØ¾ß ÇÒ Á¡  ÀåÁöÇý(°è¸íÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:04~17:10 Long-Term Follow-Up of Peripheral Pigmentary Retinopathy in Asian Patients with Danon Disease  ÀÌÁÖ¿ë(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:15~17:21 In exudative AMD, SRF should be eliminated  ±èÀçÈÖ(±è¾È°ú) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:21~17:27 In exudative AMD, SRF can be tolerated  »ç°ø¹Î(¿µ³²ÀÇ´ë) 
Åä·Ð 06¿ù 04ÀÏ  17:27~17:32 Discussion  ±èÀçÈÖ»ç°ø¹Î(±è¾È°ú¿µ³²ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:32~17:38 Áõ½Ä´ç´¢¸Á¸·º´Áõ ¼ö¼ú½Ã anti-VEGF ÁÖ»ç´Â ¾ðÁ¦Çϳª? :   ±èÁ¤¿­(Ãæ³²ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:38~17:44 Áõ½Ä´ç´¢¸Á¸·º´Áõ ¼ö¼ú½Ã anti-VEGF ÁÖ»ç´Â ¾ðÁ¦Çϳª? :   ¾ÈÁöÀ±(¼­¿ïÀÇ´ë) 
Åä·Ð 06¿ù 04ÀÏ  17:44~17:49 Discussion  ±èÁ¤¿­¾ÈÁöÀ±(Ãæ³²ÀÇ´ë¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:49~17:55 ERM ¼ö¼ú ¾ðÁ¦ Çϳª?: ¡°½Ã·Â ÀúÇÏ µî Áõ»óÀÌ ÀÖÀ» ¶§±îÁö ±â´Ù¸°´Ù¡±  ±èÁß°ï(¿ï»êÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  17:55~18:01 ERM ¼ö¼ú ¾ðÁ¦ Çϳª?: ¡°Áõ»óÀÌ ¶Ñ·ÇÇØÁö±â Àü¿¡ Á¶±â Á¦°ÅÇÑ´Ù¡±  À̼ºÁø(¼øõÇâÀÇ´ë) 
Åä·Ð 06¿ù 04ÀÏ  18:01~18:06 Discussion  ±èÁß°ïÀ̼ºÁø(¿ï»êÀÇ´ë¼øõÇâÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  18:06~18:12 ¿­°ø¸Á¸·¹Ú¸®¿¡¼­ ¸Á¸·ÇϾ×ÀÇ ¹è¾×À» À§ÇÑ ÃÖÀûÀÇ ¼ú±â´Â? :   ¹Ú¿îö(¼­¿ïÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  18:12~18:18 ¿­°ø¸Á¸·¹Ú¸®¿¡¼­ ¸Á¸·ÇϾ×ÀÇ ¹è¾×À» À§ÇÑ ÃÖÀûÀÇ ¼ú±â´Â? :   ±èö±¸(±è¾È°ú) 
Åä·Ð 06¿ù 04ÀÏ  18:18~18:23 Discussion  ¹Ú¿îö±èö±¸(¼­¿ïÀÇ´ë±è¾È°ú) 
±³À°½Ã°£ 06¿ù 04ÀÏ  18:25~18:40 Proactive treatment in nAMD  ±è¹Î(¿¬¼¼ÀÇ´ë) 
±³À°½Ã°£ 06¿ù 04ÀÏ  18:40~18:55 Early intensive treatment in DME  ¹Ú¿µÈÆ(°¡Å縯ÀÇ´ë) 
Åä·Ð 06¿ù 04ÀÏ  18:55~19:10 Discussion  ±è¹Î¹Ú¿µÈÆ(¿¬¼¼ÀÇ´ë°¡Å縯ÀÇ´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" (¿Â¶óÀÎ&¿ÀÇÁ¶óÀÎ º´Çà) 2021 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ : 2021-06-04""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û Çѱ¹ÀÇÇб³À°ÇÐȸ (¿Â¶óÀÎ) 2021 ÀÇÇб³À°¾ÆÄ«µ¥¹Ì(AME) ½ÉÈ­°úÁ¤ ÀÇ°ú´ëÇÐÀÇ »ç¸í°ú »çȸÀû Ã¥¹« : 2021-07-08
´ÙÀ½±Û ºÐ´ç¼­¿ï´ëÇб³º´¿ø (¿Â¶óÀÎ) ¾È°ú È­¿äÁý´ãȸ(Amblyopia treatment) : 2021-07-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 34 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 34 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 30 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 25 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 29 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 41 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 17 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 23 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 22 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 21 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 19 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 22 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 25 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 26 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷